Strata Critical Medical, Inc. Q1 2026 Earnings Call Summary
Key takeaways
- Q1 2026 Earnings Call Summary Moby Intelligence Thu, May 7, 2026 at 12:06 AM GMT+7 3 min read SRTA SRTAW Strata Critical Medical, Inc.
- The company achieved positive operating and free cash flow before aircraft acquisitions, marking a pivot toward sustainable cash generation as legacy passenger divestiture outflows subside.
- Management attributes the Clinical division s outperformance to the rapid adoption of Normothermic Regional Perfusion (NRP) and third-party surgical recovery, which now accounts for over half of all DCD donors.
Strata Critical Medical, Inc. Q1 2026 Earnings Call Summary Moby Intelligence Thu, May 7, 2026 at 12:06 AM GMT+7 3 min read SRTA SRTAW Strata Critical Medical, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance Drivers Revenue growth of 87% was driven by the successful integration of the new Clinical business and 32% organic growth in Logistics, validating the company s transformed economic model.
The company achieved positive operating and free cash flow before aircraft acquisitions, marking a pivot toward sustainable cash generation as legacy passenger divestiture outflows subside.
Management attributes the Clinical division s outperformance to the rapid adoption of Normothermic Regional Perfusion (NRP) and third-party surgical recovery, which now accounts for over half of all DCD donors.